A Study of Enasidenib in People With T-Cell Lymphoma

This study is testing enasidenib, a targeted drug, in people with a rare type of T-cell lymphoma called angioimmunoblastic T-cell lymphoma (AITL) that has a specific gene mutation (IDH2). The drug targets this mutation and may help shrink or control the cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AITL confirmed by biopsy with an IDH2 mutation - Your cancer has returned or did not respond to at least one prior treatment - You are in reasonably good health (able to care for yourself) **You may NOT be eligible if...** - You have a serious medical condition, abnormal lab results, or active uncontrolled infection - You are currently on immune-suppressing therapy after a stem cell transplant - You are pregnant or breastfeeding - You have chronic liver disease or active hepatitis B or C - You have previously used enasidenib - You have HIV with a detectable viral load or low CD4 count Talk to your doctor to see if this trial is right for you.